Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer

被引：7

作者：

Huang, Audris ^{[1
]}

Jayaraman, Lata ^{[1
]}

Fura, Aberra ^{[1
]}

Vite, Gregory D. ^{[1
]}

Trainor, George L. ^{[1
]}

Gottardis, Marco M. ^{[1
]}

Spires, Thomas E. ^{[1
]}

Spires, Vanessa M. ^{[1
]}

Rizzo, Cheryl A. ^{[1
]}

Obermeier, Mary T. ^{[1
]}

Elzinga, Paul A. ^{[1
]}

Todderud, Gordon ^{[1
]}

Fan, Yi ^{[1
]}

Newitt, John A. ^{[1
]}

Beyer, Sophie M. ^{[1
]}

Zhu, Yongxin ^{[1
]}

Warrack, Bethanne M. ^{[1
]}

Goodenough, Angela K. ^{[1
]}

Tebben, Andrew J. ^{[1
]}

Doweyko, Arthur M. ^{[1
]}

Gold, David L. ^{[1
]}

Balog, Aaron ^{[1
]}

机构：

[1] Bristol Myers Squibb Res & Dev, Princeton, NJ 08543 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 01期

关键词：

Prostate cancer; CYP17A1; benzimidazoles; lyase; CYP11B1; CYP21A2; cortisol; CASTRATION-RESISTANT; 17,20-LYASE INHIBITOR; ORTERONEL TAK-700; N-ARYLATION; ABIRATERONE;

D O I：

10.1021/acsmedchemlett.5b00310

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Efforts to identify a potent, reversible, non steroidal CYP17A1 lyase inhibitor with good selectivity over CYP17A1 hydroxylase and CYPs 11B1 and 21A2 for the treatment of castration-resistant prostate cancer (CRPC) culminated in the discovery of BMS-351 (compound 18), a pyridyl biaryl benzimidazole with an excellent in vivo profile. Biological evaluation of BMS-351 at a dose of 1.5 mg in castrated cynomolgus monkeys revealed a remarkable reduction in testosterone levels with minimal glucocorticoid and mineralcorticoid perturbation. Based on a favorable profile, BMS-351 was selected as a candidate for further preclinical evaluation.

引用

页码：40 / 45

页数：6

共 50 条

[41] The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer
Capper, Cameron P.
Larios, Jose M.
Sikora, Matthew J.
Johnson, Michael D.
Rae, James M.
BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (01) : 23 - 30
[42] Preclinical assessment of OrteronelA®, a CYP17A1 enzyme inhibitor in rats
Zainuddin, Mohd
Vinod, A. B.
Gurav, Sandip Dhondiram
Police, Anitha
Kumar, Avinash
Mithra, Chandan
Dewang, Purushottam
Kethiri, Raghava Reddy
Mullangi, Ramesh
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (01) : 1 - 7
[43] CYP17A1 inhibitor failure—lessons for future drug development
Nima Sharifi
Nature Reviews Urology, 2015, 12 : 245 - 246
[44] Human Cytochrome CYP17A1: The Structural Basis for Compromised Lyase Activity with 17-Hydroxyprogesterone
Mak, Piotr J.
Duggal, Ruchia
Denisov, Ilia G.
Gregory, Michael C.
Sligar, Stephen G.
Kincaid, James R.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2018, 140 (23) : 7324 - 7331
[45] Effect of CYP17A1 17,20 Lyase Inhibitors on Regulation of Adrenal Androgen Biosynthesis
Pandey, Amit V.
Udhane, Sameer S.
FASEB JOURNAL, 2016, 30
[46] Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer
Maity, Sankar N.
Titus, Mark A.
Gyftaki, Revekka
Wu, Guanglin
Lu, Jing-Fang
Ramachandran, S.
Li-Ning-Tapia, Elsa M.
Logothetis, Christopher J.
Araujo, John C.
Efstathiou, Eleni
SCIENTIFIC REPORTS, 2016, 6
[47] Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer
Sankar N. Maity
Mark A. Titus
Revekka Gyftaki
Guanglin Wu
Jing-Fang Lu
S. Ramachandran
Elsa M. Li-Ning-Tapia
Christopher J. Logothetis
John C. Araujo
Eleni Efstathiou
Scientific Reports, 6
[48] Inhibitors of 17α-hydroxylase/17,20-lyase (CYP17):: Potential agents for the treatment of prostate cancer
Njar, VCO
Brodie, AMH
CURRENT PHARMACEUTICAL DESIGN, 1999, 5 (03) : 163 - 180
[49] A Novel Compound Heterozygous CYP17A1 Variant Causes 17α-Hydroxylase/17, 20-Lyase Deficiency
Chen, Hong
Yuan, Ke
Zhang, Bingtao
Jia, Zexiao
Chen, Chun
Zhu, Yilin
Sun, Yaping
Zhou, Hui
Huang, Wendong
Liang, Li
Yan, Qingfeng
Wang, Chunlin
FRONTIERS IN GENETICS, 2019, 10
[50] CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2
Malikova, Jana
Brixius-Anderko, Simone
Udhanea, Sameer S.
Parween, Shaheena
Dick, Bernhard
Bernhardt, Rita
Pandey, Amit V.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2017, 174 : 192 - 200

← 1 2 3 4 5 →